Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Meitar and Cooley advised Gamida Cell on the offering, and Davis Polk advised the underwriter. Gamida Cell Ltd. announced the $23 million SEC-registered follow-on offering of...
You must be a Standard 1 Year member to access this content.
K&L Gates advised AVITA, and Davis Polk advised the sales agent for the offering. AVITA Medical, Inc. announced the establishment of an SEC-registered at-the-market program of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler, DLA Piper and A&L Goodbody advised Medtronic, while Davis Polk advised the representatives of the several underwriters. Medtronic Global Holdings S.C.A. issued $1 billion...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
Davis Polk and Hogan Lovells advised Precigen on the offering, and Goodwin Procter advised the underwriters involved. Precigen Inc. announced the SEC-registered offering of an aggregate of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Metalmark Capital on the deal. Metalmark Capital executed its investment of up to $50 million in Orgenesis’s U.S.-based point of care services subsidiary, Morgenesis...
You must be a Standard 1 Year member to access this content.
DLA Piper advised Medtronic Global Holdings, while Davis Polk advised the representatives of the several underwriters in the offering. Medtronic Global Holdings S.C.A. executed its offering of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the underwriters in the offering while Jones Day advised GenScript Biotech Corporation. Legend Biotech Corporation executed its $403 million SEC-registered follow-on offering of 9,361,000...
You must be a Standard 1 Year member to access this content.
